## Biocidal Products Committee (BPC)

Opinion on the application for approval of the active substance:
Hydrogen peroxide
Product type: 1

ECHA/BPC/39/2015

Adopted
2 February 2015

## Opinion of the Biocidal Products Committee

## on the application for approval of the active substance hydrogen peroxide for product type 1

In accordance with Article 89(1) of Regulation (EU) No 528/2012 of the European Parliament and of the Council 22 May 2012 concerning the making available on the market and use of biocidal products (BPR), the Biocidal Products Committee (BPC) has adopted this opinion on the approval in product type 1 of the following active substance:

| Common name: | Hydrogen peroxide |
| :--- | :--- |
| Chemical name(s): | Hydrogen peroxide |
| EC No.: | $231-765-0$ |
| CAS No.: | $\mathbf{7 7 2 2 - 8 4 - 1}$ |

## Existing active substance

This document presents the opinion adopted by the BPC, having regard to the conclusions of the evaluating Competent Authority. The assessment report, as a supporting document to the opinion, contains the detailed grounds for the opinion.

## Process for the adoption of BPC opinions

Following the submission of an application by the members of the CEFIC Peroxygens Sector Group, Subgroup Hydrogen peroxide on 26 July 2007, the evaluating Competent Authority Finland submitted an assessment report and the conclusions of its evaluation to the Commission on 2 August 2013. In order to review the assessment report and the conclusions of the evaluating Competent Authority, the Agency organised consultations via the BPC and its Working Groups. Revisions agreed upon were presented and the assessment report and the conclusions were amended accordingly.

## Adoption of the BPC opinion

## Rapporteur: BPC member for Finland

The BPC opinion on the approval of the active substance hydrogen peroxide in product type 1 was adopted on 2 February 2015.

The BPC opinion was adopted by consensus.

## Detailed BPC opinion and background

## 1. Overall conclusion

The overall conclusion of the BPC is that hydrogen peroxide in product type 1 may be approved. The detailed grounds for the overall conclusion are described in the assessment report.

## 2. BPC Opinion

### 2.1. BPC Conclusions of the evaluation

## a) Presentation of the active substance including the classification and labelling of the active substance

This evaluation covers the use of hydrogen peroxide in product type 1 , the evaluation does not cover the active substances or biocidal products containing hydrogen peroxide generated in situ. The active substance hydrogen peroxide is manufactured as its aqueous solutions containing $35 \%$ to $<70 \%$ (by weight) hydrogen peroxide. The assessment covers risks from use of biocidal products containing hydrogen peroxide up to 49.9 \%. For toxicology and ecotoxicology assessments, concentrations or amounts of hydrogen peroxide always refer to pure (100\%) hydrogen peroxide unless stated otherwise.
There is no significant impurity (concentration $>0.1 \%$ ) present in the substance. Impurities with a concentration of each $<1 \mathrm{mg} / \mathrm{kg}$ are lead, mercury, cadmium and arsenic. Hydrogen peroxide reacts with organic molecules, which are oxidized and even split. Target molecules include proteins, nucleic acids and lipids. Chemical reactions may lead to deactivation of critical cellular functions and cell death. Depending on the concentration hydrogen peroxide may cause local irritation or corrosion of biological tissues.
The physico-chemical properties of the active substance and biocidal product have been evaluated and are deemed acceptable for the appropriate use, storage and transportation of the active substance and biocidal products.
Validated analytical methods are available for the active substance as manufactured. Analytical methods for the determination of hydrogen peroxide in food and feed stuffs are not deemed necessary. Certain analytical methods (water, air) are required as further information (See 2.5 Requirements for further information).
In 2008 hydrogen peroxide has been included in Annex VI of Regulation (EC) No 1272/2008 (CLP Regulation). The classification, as presented in the Table, is the translation of the harmonised classification made for the substance under Directive 67/548/EEC. However, the evaluating Competent Authority (Finland) is of the opinion that based on the data evaluated in the present assessment report, Aquatic Chronic 3 (H412) classification should be applied according to the 2 ATP to CLP Regulation (Regulation (EC) No 286/2011). Regarding the acute toxicity classification, the eCA is of the opinion that the acute oral toxicity can be confirmed as category 4 based on the data presented in the present assessment report. For the acute inhalation toxicity category 4 some uncertainty remains, and therefore the minimum classification as category 4 cannot be confirmed. The eCA however considers that submission of a CLH dossier to ECHA to revise the current harmonised classification is of low priority nor necessary at the moment since from the risk management point of view the changes would not substantially increase the level of safety.

| Classification according to the CLP Regulation |  |  |
| :--- | :--- | :---: |
| Hazard Class and |  |  |
| Category Codes | Ox. Liq. 1 $\quad$ H271 <br> Acute Tox. 4* H332 |  |
|  | Acute To. 4* H302 |  |
|  | Skin Corr. 1A H314 |  |

## b) Intended use, target species and effectiveness

Hydrogen peroxide products (35\% (w/w) and 49.9\% (w/w) hydrogen peroxide respectively) are used for topical disinfection of human skin with a general disinfecting claim. The product has to be diluted in water to $4.9 \%(w / w)$ solutions prior to application. The dilution is performed by professionals e.g. pharmacists. The use of hydrogen peroxide as a leave on skin disinfectant is not restricted to professionals. Hence, primary exposure for non-professionals is possible.

Target organisms include bacteria, fungi and viruses. The data on hydrogen peroxide and the representative biocidal product have demonstrated sufficient efficacy against at least one target species (fungi) at the lowest in-use concentration (4.9\%) evaluated. Resistance is not observed due to the low specificity of reactions of hydrogen peroxide.

## c) Overall conclusion of the evaluation including need for risk management measures

## Human health

The adverse effects of hydrogen peroxide in humans are limited to local effects at the site of first contact with the body and to embolism in rare accidental cases with very high concentrations. No clear systemic effects were observed, which is plausible in the light of the mode of action, i.e. direct chemical reactivity leading to rapid degradation. Corrosion and/or irritation of the skin and mucous membranes are the most prominent observations in the variety of animal studies. These effects are concentration' dependent with no or only minor dependence on exposure duration.

Besides the direct chemical reactivity underlying the irritation and corrosion related lesions, hydrogen peroxide causes sensory irritation.

The table below summarises the exposure scenarios assessed.

| Summary table: human health scenarios |  |  |
| :---: | :--- | :--- |
| Scenario | Primary or secondary exposure, <br> exposed group and description of <br> scenario | Acceptable or <br> unacceptable |
| Mixing and loading | Primary exposure: Professionals <br> Handling concentrated hydrogen <br> peroxide solution and diluting with <br> water | Acceptable with gloves, <br> coverall and goggles/face <br> shield (local effects). <br> Respiratory protective <br> equipment (RPE) if <br> insufficient ventilation or <br> no local exhaust <br> ventilation (LEV). |
| Application | Primary exposure: Professionals <br> Hand disinfection, hospital use (25 <br> applications) and food industry use | Acceptable |
| Primary exposure: Non-professionals <br> Hand disinfection, infrequent use |  |  |

The use of hydrogen peroxide in hand disinfection is acceptable with the $4.9 \%$ in-use concentration. Personal protective equipment (PPE) is required for professionals in the mixing and loading scenario because of the skin and eye irritation properties of concentrated hydrogen peroxide solution. For non-professionals use of hydrogen peroxide as skin disinfectant is acceptable.

No secondary (indirect) exposure is assumed because no residual hydrogen peroxide appears either in food or in the environment.

## Environment

The table below summarises the exposure scenarios assessed.

| Summary table: environment scenarios |  |
| :---: | :--- |
| Scenario | Description of scenario including <br> environmental compartments |
| Disinfection of human skin: <br> Tonnage scenario <br> (private use) | Waste water emission to STP (sewage treatment <br> plant). Emissions to surface water, soil and <br> groundwater via STP. |
| Disinfection of human skin: <br> Tonnage scenario <br> (professional use) | Waste water emission to STP. Emissions to surface <br> water, soil and groundwater via STP. |
| Disinfection of human skin: <br> Consumption scenario <br> (professional use) | Waste water emission to STP. Emissions to surface <br> water, soil and groundwater via STP. |

Hydrogen peroxide decomposes rapidly into water and oxygen in different environmental compartments, i.e. in surface water, soil, active sludge and air. In addition, hydrogen peroxide decomposes already in sewage before reaching the STP. All evaluated scenarios are identified as safe uses.

### 2.2. Exclusion, substitution and POP criteria

### 2.2.1. Exclusion and substitution criteria

The table below summarises the relevant information with respect to the assessment of exclusion and substitution criteria:

| Property | Conclusions |  |
| :---: | :---: | :---: |
|  | Carcinogenicity (C) | No classification required |
|  | Mutagenicity (M) | No classification required |
|  | Toxic for reproduction (R) | No classification required |
| Respiratory sensitisation <br> properties | No classification required |  |
| PBT and vPvB properties | Persistent (P) or very <br> Persistent (vP) | Not P or vP |
|  | Bioaccumulative (B) or very <br> Bioaccumulative (vB) | Not B or vB |
|  | Toxic (T) |  |
| Endocrine disrupting <br> properties | Hydrogen peroxide is not considered to have endocrine <br> disrupting properties |  |

Consequently, the following is concluded:
Hydrogen peroxide does not meet the exclusion criteria laid down in Article 5 of Regulation (EU) No 528/2012.
Hydrogen peroxide does not meet the conditions laid down in Article 10 of Regulation (EU) No 528/2012, and is therefore not considered as a candidate for substitution. The exclusion and substitution criteria were assessed in line with the "Note on the principles for taking decisions on the approval of active substances under the BPR"1 and in line with "Further guidance on the application of the substitution criteria set out under article 10(1) of the BPR ${ }^{\prime 2}$ agreed at the $54^{\text {th }}$ and $58^{\text {th }}$ meeting respectively, of the representatives of Member States Competent Authorities for the implementation of Regulation 528/2012 concerning the making available on the market and use of biocidal products. This implies that the assessment of the exclusion criteria is based on Article $5(1)$ and the assessment of substitution criteria is based on Article 10(1)(a, b, d, e and f).

### 2.2.2. POP criteria

Hydrogen peroxide does not fulfil criteria for being a persistent organic pollutant (POP). Hydrogen peroxide does not have potential for long-range transboundary atmospheric transport.

[^0]
### 2.3. BPC opinion on the application for approval of the active substance hydrogen peroxide in product type 1

In view of the conclusions of the evaluation, it is proposed that hydrogen peroxide shall be approved and be included in the Union list of approved active substances, subject to the following specific conditions:

1. Specification: minimum purity of the active substance evaluated: The active substance as manufactured is an aqueous solution of $350-<700 \mathrm{~g} / \mathrm{kg}$ ( $35-<70 \%$, by weight) solution of hydrogen peroxide. The theoretical (calculated) dry weight specification: minimum purity of hydrogen peroxide is $995 \mathrm{~g} / \mathrm{kg}$ ( $99.5 \%$ by wt ).
2. The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance.
3. For professional users, safe operational procedures and appropriate organizational measures shall be established.
Hydrogen peroxide gives rise to concern for human health as it is classified with skin corrosive of category 1 A and specific target organ toxicant by single exposure mentioned in Article 28(2)(a) of the BPR. Therefore inclusion in Annex I of Regulation (EU) $528 / 2012$ is not acceptable.

### 2.4. Elements to be taken into account when authorising products

1. A qualitative risk assessment should be performed for the local effects taking into account the classification of the product and it's in use dilutions.
2. Since the assessment covers risks from use of biocidal products containing hydrogen peroxide up to 49.9 \%, additional risk assessment should be performed if approvals for biocidal products with concentration of $50 \%$ or higher are applied for.
3. For mixing and loading, when diluting the concentrated solutions prior to application, the need for appropriate personal protective equipment should be considered.
4. Regulation (EU) No 98/2013 on the marketing and use of Explosive Precursors has to be considered for applications for authorisation for non-professional use.

### 2.5. Requirement for further information

Sufficient data have been provided to verify the conclusions on the active substance, permitting the proposal for the approval of hydrogen peroxide. However, further data shall be required as detailed below:

1. A new analytical method for the determination of hydrogen peroxide in air should be submitted. Data must be provided to the evaluating Competent Authority (Finland) as soon as possible but no later than 6 months before the date of approval of the active substance.
2. A new analytical method for the determination of hydrogen peroxide in water should be submitted. Data must be provided to the evaluating Competent Authority (Finland) as soon as possible but no later than 6 months before the date of approval of the active substance.
3. Some sources could not be validated. Therefore further data will need to be submitted as specified in the confidential annex of the evaluation to the evaluating Competent Authority (Finland) as soon as possible but no later than 6 months before the date of approval of the active substance.

[^0]:    ${ }^{1}$ See document: Note on the principles for taking decisions on the approval of active substances under the BPR (available from https://circabc.europa.eu/d/a/workspace/SpacesStore/c41b4ad4-356c-4852-9512-62e72cc919df/CA-March14-Doc.4.1\%20-\%20Final\%20-\%20Principles\%20for\%20substance\%20approval.doc) 2 See document: Further guidance on the application of the substitution criteria set out under article 10(1) of the BPR (available from https://circabc.europa.eu/d/a/workspace/SpacesStore/dbac71e3-cd70-4ed7-bd40-fc1cb92cfe1c/CA-Nov14-Doc.4.4\%20-\%20Final\%20-\%20Further\%20guidance\%20on\%20Art10(1).doc)

